MedPath

Prospective observational study on the evaluation of antitumor effect of simultaneous combination chemoradiotherapy due to change in Apparent Diffusion Coefficient values of esophageal squamous cell carcinoma in magnetic resonance diffusion emphasized imaging

Not Applicable
Conditions
Esophageal squamous cell carcinoma
Registration Number
JPRN-UMIN000031672
Lead Sponsor
Tohoku University
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up continuing
Sex
All
Target Recruitment
40
Inclusion Criteria

Not provided

Exclusion Criteria

(1) Patients with history of chemotherapy or radiotherapy to the chest against esophageal cancer or other diseases. (2) Cases after esophagus cancer mucosal resection. (3) Simultaneous duplicated cancer cases of active requiring treatment. Or cases with a disease-free period of less than 3 years even if they are metachronous. (4) Cases with severe complications such as poorly controlled diabetes, collagen diseases, heart diseases, lung diseases, kidney diseases, psychiatric disorders and the like which are expected to be unable to withstand the present test protocol (5) Pregnant women, lactating women and cases of possible pregnancy. (6) Cases in which active infection has been proven and has a fever of 38 degrees or more. (7) Cases in which steroids are routinely used. (8) Case with pacemaker or internal defibrillator. (9) Cases in which confirmation of intention can not be performed. (10) Cases in which MRI imaging can not be performed. (11) Other cases that the doctor in charge deemed inappropriate as a subject.

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Relationship between changes within the 14 days before radiochemotherapy by ADC value measurement and at 20 Gy point after treatment start and tumor reduction ratio
Secondary Outcome Measures
NameTimeMethod
Overall survival rate and relapse-free survival rate and prognostic factors
© Copyright 2025. All Rights Reserved by MedPath